BGB DXP593
BGB-DXP593-101
Phase 1 small_molecule completed
Quick answer
BGB DXP593 for Covid19 is a Phase 1 program (small_molecule) at BeiGene with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene
- Indication
- Covid19
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed